The final appraisal document published today by the health technology assessment body NICE provides more insight into the health technology assessment body’s recent recommendation on Kymriah’s use in young people with leukemia.
Health technology assessment body NICE today published the reasons why it decided in September that Novartis’s CAR T-cell therapy Kymriah (tisagenlecleucel) should not be routinely used by England’s National Health Service for young people with leukemia but should instead be provided via the Cancer Drugs Fund.
Uncertainties in the evidence for Kymriah, including long-term survival data and the cost of subsequent stem cell treatments, raised questions...
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
